Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 14:7:23.
doi: 10.1186/s40164-018-0115-8. eCollection 2018.

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin

Affiliations

Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin

Satish Maharaj et al. Exp Hematol Oncol. .

Abstract

Background: Heparin-induced antibodies (HIA) are responsible for causing heparin-induced thrombocytopenia and thrombosis. Research has shown that the temporality of heparin-induced antibodies does not follow the classic immunologic response. The immunobiology of HIA generation remains unclear with varying in vitro and in vivo data. Outpatients undergoing hemodialysis (HD) are exposed to heparin chronically. The HIA immune response can therefore be investigated in vivo in this population.

Methods: We examined the time between the start of HD using unfractionated heparin and HIA levels in 212 outpatients during a 6-year period. Antibodies were detected on enzyme-linked immunosorbent assay. HIA levels were analyzed to determine significance of the trend over time. HIA subgroups were also analyzed for correlation with subsequent thrombotic events and platelet count during follow up.

Results: Overall, the HIA response in HD was found to peak early with waning antibody response despite continued exposure to heparin. The peak prevalence of a strong immune response (optical density > 1.000) was early and short lived, while weaker immune response (optical density 0.400-1.000) persisted for the first 6 months then declined. The mean follow-up time per patient was 2.3 ± 1.4 years. Despite circulating HIA, including high titers, no patients developed HIT in this sample. There was no association between HIA and thrombocytopenia. There was increased incidence of thrombosis in patients with strong HIA compared to other groups, but this did not achieve statistical significance.

Conclusions: The data suggest a significant temporal pattern of HIA in outpatients undergoing HD using unfractionated heparin. Positive HIA was not found to be significantly associated with thrombocytopenia or thrombosis risk in these patients. However, while not achieving statistical significance, subsequent thrombotic events occurred most frequently in the strong positive HIA group (optical density > 1.000). Further research into HIA and risk of thrombosis in this population is needed.

Keywords: Antibodies; HIT; Hemodialysis; Heparin; Thrombocytopenia; Thrombosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of HIA in chronic hemodialysis using unfractionated heparin. The antibody responses demonstrate continuous unimodal distribution skewed to the right with high OD outliers
Fig. 2
Fig. 2
Temporality of positive HIA in hemodialysis using UFH. Anti-PF4/heparin antibodies are produced along a continuum, but there is waning of the immune response with increased time on hemodialysis. The strongest antibody generation is within the first 6 months
Fig. 3
Fig. 3
Plot of all HIA levels (OD) stratified by time and compared for significance. The box plots show the 25th percentile to the 75th percentile, with the midline representing the median and separating the two quartiles. The first whisker (below) shows the lowest 25%; while the second whisker (upper) shows the top 25%, excluding outliers. The mean OD is denoted by the “X” marker. Outliers are designated by values greater than 1.5 times the interquartile range. A significant decline in OD was noted after 6 months

Similar articles

Cited by

References

    1. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958;76(2):219–225. doi: 10.1001/archsurg.1958.01280200041005. - DOI - PubMed
    1. Krauel K, Pötschke C, Weber C, et al. Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–1378. doi: 10.1182/blood-2010-08-301424. - DOI - PubMed
    1. Haile LA, Rao R, Polumuri SK, et al. PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. Thromb Res. 2017;159:39–47. doi: 10.1016/j.thromres.2017.09.018. - DOI - PubMed
    1. Hayes V, Johnston I, Arepally GM, et al. Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. J Clin Invest. 2017;127(3):1090–1098. doi: 10.1172/JCI90958. - DOI - PMC - PubMed
    1. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009;113(20):4970–4976. doi: 10.1182/blood-2008-08-173062. - DOI - PubMed

LinkOut - more resources